Using EEG-Guided Basket and Umbrella Trials in Psychiatry: A Precision Medicine Approach for Cognitive Impairment in Schizophrenia
Due to advances over the last several decades, many fields of medicine are moving toward a precision medicine approach where treatments are tailored to nuanced patient factors. While in some disciplines these innovations are commonplace leading to unique biomarker-guided experimental medicine trials...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-11-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fpsyt.2018.00554/full |
id |
doaj-029c1d88dd9e4f6ba79b34108887d92b |
---|---|
record_format |
Article |
spelling |
doaj-029c1d88dd9e4f6ba79b34108887d92b2020-11-24T21:47:47ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402018-11-01910.3389/fpsyt.2018.00554416872Using EEG-Guided Basket and Umbrella Trials in Psychiatry: A Precision Medicine Approach for Cognitive Impairment in SchizophreniaYash B. Joshi0Gregory A. Light1Gregory A. Light2Department of Psychiatry, University of California, San Diego, La Jolla, CA, United StatesDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, United StatesVISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Health Care System, San Diego, CA, United StatesDue to advances over the last several decades, many fields of medicine are moving toward a precision medicine approach where treatments are tailored to nuanced patient factors. While in some disciplines these innovations are commonplace leading to unique biomarker-guided experimental medicine trials, there are no such analogs in psychiatry. In this brief review, we will overview two unique biomarker-guided trial designs for future use in psychiatry: basket and umbrella trials. We will illustrate how such trials could be useful in psychiatry using schizophrenia as a candidate illness, the EEG measure mismatch negativity as the candidate biomarker, and cognitive impairment as the target disease dimension.https://www.frontiersin.org/article/10.3389/fpsyt.2018.00554/fullschizophreniamismatch negativitybiomarkerclinical trialcognitive impairment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yash B. Joshi Gregory A. Light Gregory A. Light |
spellingShingle |
Yash B. Joshi Gregory A. Light Gregory A. Light Using EEG-Guided Basket and Umbrella Trials in Psychiatry: A Precision Medicine Approach for Cognitive Impairment in Schizophrenia Frontiers in Psychiatry schizophrenia mismatch negativity biomarker clinical trial cognitive impairment |
author_facet |
Yash B. Joshi Gregory A. Light Gregory A. Light |
author_sort |
Yash B. Joshi |
title |
Using EEG-Guided Basket and Umbrella Trials in Psychiatry: A Precision Medicine Approach for Cognitive Impairment in Schizophrenia |
title_short |
Using EEG-Guided Basket and Umbrella Trials in Psychiatry: A Precision Medicine Approach for Cognitive Impairment in Schizophrenia |
title_full |
Using EEG-Guided Basket and Umbrella Trials in Psychiatry: A Precision Medicine Approach for Cognitive Impairment in Schizophrenia |
title_fullStr |
Using EEG-Guided Basket and Umbrella Trials in Psychiatry: A Precision Medicine Approach for Cognitive Impairment in Schizophrenia |
title_full_unstemmed |
Using EEG-Guided Basket and Umbrella Trials in Psychiatry: A Precision Medicine Approach for Cognitive Impairment in Schizophrenia |
title_sort |
using eeg-guided basket and umbrella trials in psychiatry: a precision medicine approach for cognitive impairment in schizophrenia |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Psychiatry |
issn |
1664-0640 |
publishDate |
2018-11-01 |
description |
Due to advances over the last several decades, many fields of medicine are moving toward a precision medicine approach where treatments are tailored to nuanced patient factors. While in some disciplines these innovations are commonplace leading to unique biomarker-guided experimental medicine trials, there are no such analogs in psychiatry. In this brief review, we will overview two unique biomarker-guided trial designs for future use in psychiatry: basket and umbrella trials. We will illustrate how such trials could be useful in psychiatry using schizophrenia as a candidate illness, the EEG measure mismatch negativity as the candidate biomarker, and cognitive impairment as the target disease dimension. |
topic |
schizophrenia mismatch negativity biomarker clinical trial cognitive impairment |
url |
https://www.frontiersin.org/article/10.3389/fpsyt.2018.00554/full |
work_keys_str_mv |
AT yashbjoshi usingeegguidedbasketandumbrellatrialsinpsychiatryaprecisionmedicineapproachforcognitiveimpairmentinschizophrenia AT gregoryalight usingeegguidedbasketandumbrellatrialsinpsychiatryaprecisionmedicineapproachforcognitiveimpairmentinschizophrenia AT gregoryalight usingeegguidedbasketandumbrellatrialsinpsychiatryaprecisionmedicineapproachforcognitiveimpairmentinschizophrenia |
_version_ |
1725895616347766784 |